LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $86.50 Average PT from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus rating of “Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $90.33.

A number of analysts have issued reports on the company. JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Monday, August 12th. Roth Mkm reissued a “buy” rating and issued a $100.00 target price on shares of LeMaitre Vascular in a report on Friday, May 31st. Barrington Research boosted their target price on LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, Roth Capital raised LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the transaction, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 12,976 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the completion of the sale, the chief executive officer now owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,251 shares of company stock worth $3,714,994. Company insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of the stock. Truist Financial Corp grew its holdings in LeMaitre Vascular by 92.1% during the 2nd quarter. Truist Financial Corp now owns 7,054 shares of the medical instruments supplier’s stock valued at $580,000 after buying an additional 3,381 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after buying an additional 90,573 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in LeMaitre Vascular by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,469 shares of the medical instruments supplier’s stock valued at $861,000 after buying an additional 583 shares during the last quarter. AQR Capital Management LLC grew its holdings in LeMaitre Vascular by 68.6% during the 2nd quarter. AQR Capital Management LLC now owns 22,569 shares of the medical instruments supplier’s stock valued at $1,857,000 after buying an additional 9,183 shares during the last quarter. Finally, Alpha DNA Investment Management LLC acquired a new stake in LeMaitre Vascular during the 2nd quarter valued at $499,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

LMAT opened at $91.67 on Tuesday. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $91.78. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of 60.71, a PEG ratio of 2.63 and a beta of 0.89. The business has a fifty day moving average price of $84.26 and a 200 day moving average price of $74.50.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. The firm had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. During the same period in the previous year, the firm posted $0.37 EPS. LeMaitre Vascular’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, research analysts anticipate that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is presently 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.